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Preparation of restricted access medium using antibody as the ligand binding agent molecule.
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Antibody structure in protected and unprotected regions before and after cleaving
agent treatment using the Hydrazide method.
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Antibody structure in protected and unprotected regions before and
after cleaving agent treatment using the Aldehyde (Schiff base) method.
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Effect of support pore size on the percentage of Fab regions retained.
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Effect of support pore size on the percentage of Fab regions remaining
following cleaving agent treatment.
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Effect of time on the amount of retained antibody remaining after
cleaving agent treatment.
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Effect of cleaving agent concentration.
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Retention of fluorescein or fluorescein-BSA by an anti-fluorescein
restricted access media.
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Percent extraction of fluorescein or fluorescein by an anti-fluorescein
restricted access media.
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Restricted access media with protected and unbound protein.
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Amount of Human Serum Albumin retained using a hydrazide-activated

support with pore sizes ranging from 50 A to 1000 A.
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1.
RESTRICTED ACCESSMEDIA AND
METHODS FOR MAKING RESTRICTED
ACCESSMEDIA
CROSS-REFERENCE TO RELATED
APPLICATIONS

This application claims the benefit of U.S. Provisional
Patent Application No. 61/092,546 filed Aug. 28, 2008 under
35 USC 119(e) and incorporated herein by reference in its
entirety.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH ORDEVELOPMENT
GOVERNMENTAL SUPPORT
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the adsorption of a ligand binding agent to a surface, the
binding of one ligand binding agent to a second ligand bind
ing agent, or the formation of a complex between the ligand
binding agent and Support. Entrapment or encapsulation tech
niques involve the physical containment of a molecule in a
support. Previously described entrapment methods are lim
ited to particular types of Supports (i.e., Sol gels) and are
useful only with relatively small Volume systems (i.e., capil
lary columns in HPLC). Accordingly, a need exists for non
covalent retention of molecules that is applicable to a variety
of different Support materials and molecules to produce Sup
ports containing noncovalently linked agents that closely
mimic the behavior of these same agents in their native
unbound form.

15

SUMMARY OF THE INVENTION

This invention was made with Government support under
Grant #R01 GMO44931 and Grant #R01 DKO69629, both

awarded by the National Institutes of Health. The government
has certain rights to this invention.
BACKGROUND OF THE INVENTION

Restricted access media (RAM) have been used for many
years in work with biological samples to combine the features
of size exclusion chromatography with partition or ion-ex
change chromatography. The Support in RAM is typically
porous silica or a porous polymer having a non-adsorptive
and hydrophilic outer Surface and an interior stationary phase
that can retain analytes through partitioning or ionic interac
tions. This provides a medium in which only low mass Sub
stances are retained, while larger agents such as proteins elute
in the excluded volume. RAM have been used for analysis of
drugs, peptides, and endogenous Substances in complex
samples such as serum, blood, urine, and cell cultures.
Many Small molecules Such as drugs and hormones bind
proteins and/or other agents that are present in a sample. This
gives rise to both a free (non-bound) form and a bound form
of the small molecule in the sample. Traditional methods for
separating free and bound forms of Small molecules include
equilibrium dialysis and ultrafiltration, which can involve
long analysis times, are often labor intensive, and usually
require additional analytical methods for actual measurement
of the free form. These methods involve a size separation
between the free form and bound form. Non-affinity
restricted access media columns have been used for separa
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tion of free and bound forms, however, these columns have

given only partial separation and work for only some ana
lytes. Ultrafast extraction of free forms by small immobilized
antibody columns have been reported, however, these assays
require using an antibody Support that can recognize and bind
the free form without having significant interactions with the
bound form. Accordingly, a need exists for a media having
high selectivity towards free forms of the small molecule but
without significant interactions with bound forms and meth
ods for making these media.
One challenge presented by immobilized or covalently
linked molecules is to attach them to supports while retaining
their behavior in their native form. Covalently linking or
immobilization of molecules directly to the Support may
affect the molecule's activity if the molecule is linked at or
near its active site. For example, antibodies attached to a
Support by their F, fragment may decrease and/or lose their
ability to bind antigen. Covalent immobilization may also
result in multisite attachment and random orientation of the

molecule, which often leads to decreased or complete loss of
activity. Noncovalent immobilization techniques can involve

50

55

60

65

The invention generally relates to Restricted Access Media
that comprise protected ligand binding agents or enzymes and
methods of making Such Restricted Access Media Supports.
In certain embodiments, the present invention provides new
RAM supports and methods for making RAM supports. In
one aspect, the RAM Supports contain covalently bound
ligand binding agent molecules in protected regions. Another
aspect provides methods for preparing a restricted access
media containing covalently bound ligand binding agent mol
ecules in protected regions. In another aspect, the RAM Sup
ports contain unbound ligand binding agent or enzyme mol
ecules retained by a capping agent. A further aspect provides
methods for preparing a restricted access media containing
unbound ligand binding agent or enzyme molecules retained
by a capping agent.
In certain embodiments, the invention provides a restricted
access media comprising a Support wherein a plurality of
protected regions of said Support contain one or more
covalently linked ligand binding agent molecule(s) and
wherein a plurality of unprotected regions of said Support
contain one or more covalently linked blocking agent mol
ecule(s). In certain embodiments, the Support can comprise
an inorganic material, a biological material, an organic mate
rial, an organic polymer, a composite Support, or a modified
Support. In certain embodiments, the Support can comprise
silica, glass, alumina, Zirconia, silver, gold, agarose, dextran,
cellulose, polystyrene, polymethacrylate, polyamide, agar
ose-coated quartz, agarose-coated stainless steel, or coated
polystyrene/divinylbenzene. In certain embodiments, the
ligand binding agent molecule can comprise a protein, a
glycoprotein, a DNA, a RNA, a nucleoprotein, or a carbohy
drate containing agent. In certain embodiments, the blocking
agent molecule can comprise a Sub-fragment of the ligand
binding agent molecule wherein ligand binding activity is
reduced or eliminated. In certain embodiments, the blocking
agent molecule can also comprise a Sub-fragment of a linking
agent. In certain embodiments, the linking agent can com
prise a carbohydrate, a nucleic acid, or a peptide.
In certain embodiments, the invention provides methods
for preparing a restricted access media comprising incubating
an activated Support with a solution comprising a plurality of
ligand binding agent molecules to form a ligand bound Sup
port wherein the ligand binding agent molecule is covalently
linked to the Support; treating the ligand bound Support with
a size restricted cleaving agent that cleaves one or more ligand
binding agent molecule(s) or one or more linking agent mol
ecules bound to unprotected regions of the Support; and
removing the cleaving agent and unbound fragments of
cleaved ligand binding agent molecules or linking agent mol
ecules, thereby preparing a restricted access media. In certain
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embodiments, the Support can comprise silica, glass, alu
mina, Zirconia, silver, gold, agarose, dextran, cellulose, poly
styrene, polymethacrylate, polyamide, agarose-coated
quartz, agarose-coated Stainless Steel, or coated polystyrene?
divinylbenzene. In certain embodiments, the Support can

comprise a pore size in the range of about 50 A to about 500
A. In certain embodiments, the size restricted cleaving agent

can comprise an enzyme or ribozyme. In certain embodi
ments, the ligand binding agent molecule can comprise a
protein, a glycoprotein, a DNA, a RNA, a nucleoprotein, or a
carbohydrate containing agent. In certain embodiments, the
ligand binding agent molecule can be covalently linked to the
Support by an amine group, a sulfhydryl group, a carboxylate
group, a carbonyl group, or a combination thereof. In certain
embodiments, the ligand binding agent molecule can further
comprise an activated ligand binding agent molecule. In cer
tain embodiments, the linking agent can comprise a protein, a
glycoprotein, a DNA, a RNA, a nucleoprotein, or a carbohy
drate containing agent. In certain embodiments, the size
restricted cleaving agent can comprise a protease. In certain
embodiments, the protease can comprise a cysteine protease,
a serine protease, a threonine protease, an aspartate protease,
or a metalloprotease. In certain embodiments, the activated
Support can be activated by an aldehyde or a hydrazide.
In certain embodiments, the invention provides restricted
access media comprising a Support wherein a plurality of
protected regions of the Support contain one or more unbound
ligand binding agent(s) or enzyme molecules and wherein the
ligand binding agent(s) or enzyme molecule(s) are retained in
the protected regions by a capping agent. In certain embodi
ments, the protected region of the Support can be on a surface,
in an interior pore, or a combination thereof. In certain
embodiments, the Support can comprise an inorganic mate
rial, a biological material, an organic material, an organic
polymer, a composite Support, or a modified Support. In cer
tain embodiments, the Support can comprise silica, glass,
alumina, Zirconia, silver, gold, agarose, dextran, cellulose,
polystyrene, polymethacrylate, polyamide, agarose-coated
quartz, agarose-coated Stainless Steel, or coated polystyrene?
divinylbenzene. In certain embodiments, the unbound ligand
binding agent can comprise a protein, a glycoprotein, a DNA,
a RNA, a nucleoprotein, a carbohydrate containing agent, a
lipoprotein, or a combination thereof. In certain embodi
ments, the capping agent can comprise a glycoprotein, a
glycolipid, a carbohydrate containing agent, or a combination
thereof. In certain embodiments, the carbohydrate containing
agent can comprise glycogen, dextran, agarose, or cellulose.
In certain embodiments, the invention provides methods
for preparing a restricted access media comprising incubating
an activated Support with a solution comprising: i) a ligand
binding agent or an enzyme molecule and ii) an activated
capping agent; and removing unbound capping agent from
said incubated Support, thereby preparing the restricted
access media comprising a Support wherein a plurality of
protected regions of said support contain one or more
unbound ligand binding agent(s) or enzyme molecule(s) and
wherein said ligand binding agent(s) or enzyme molecule(s)
are retained in said protected regions by said capping agent. In
certain embodiments, the method can further comprise wash
ing the restricted access media with a solution to deactivate
bound capping agent. In certain embodiments, the Solution to
deactivate bound capping agent can comprise a hydrazide
containing agent or an amine-containing agent. In certain
embodiments, the protected region of the activated Support is
on a surface, in an interior pore, or a combination thereof. In
certain embodiments, the ligand binding agent or the enzyme
molecule and the activated capping agent can be incubated
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together with the activated Support or incubated separately
with the activated Support. In certain embodiments, the acti
vated Support can comprise silica, glass, alumina, Zirconia,
silver, gold, agarose, dextran, cellulose, polystyrene, poly
methacrylate, polyamide, agarose-coated quartz, agarose
coated stainless steel, or coated polystyrene? divinylbenzene.
In certain embodiments, the activated Support can be acti
vated by a hydrazide group, an amine group, an aldehyde
group, or a combination thereof. In certain embodiments, the
activated capping agent can comprise a glycoprotein, a gly
colipid, or a carbohydrate-containing agent. In certain
embodiments, the carbohydrate containing agent can com
prises glycogen, dextran, agarose, or cellulose. In certain
embodiments, the activated capping agent can be activated by
oxidization with an oxidizing agent. In certain embodiments,
the oxidizing agent comprises a periodate, a periodate-related
chemical, or an enzyme treatment. In certain embodiments,
the activated capping agent can comprise an oxidized capping
agent, a hydrazide-containing agent, an amine-containing
agent, or hydrazine. In certain embodiments, the Support can

comprise a porous support with a pore size of about 50 A to
about 1000A. In certain embodiments, the enzyme molecule
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can comprise an oxidoreductase, a transferase, a hydrolase, a
lyase, an isomerase, or a ligase.
In certain embodiments, the invention provides kits for
preparing a restricted access media comprising: i) a Support
that is Substantially free of ligand binding agent molecules
and ii) a size restricted cleaving agent. In certain embodi
ments, the kits can further comprise any one of: 1) instruc
tions for the use thereof, 2) a solution for activating the
Support, 3) an activated Support, 4) a ligand binding agent
molecule that is not covalently linked to the support or a
linking agent that is not covalently linked to the Support; or
any combination of elements 1, 2, 3, and/or 4. In certain
embodiments of any of the foregoing kit embodiments, the
restricted access media that is prepared comprises a Support
wherein a plurality of protected regions of said support con
tain one or more covalently linked ligand binding agent mol
ecules and wherein a plurality of unprotected regions of said
Support contain one or more covalently linked blocking agent
molecule(s).
In certain embodiments, the invention provides kits com
prising restricted access media comprising: i) a Support
wherein a plurality of protected regions of the Support contain
one or more covalently linked ligand binding agent molecules
and wherein a plurality of unprotected regions of the Support
contain one or more covalently linked blocking agent mol
ecule(s) and ii) at least one container. In certain embodiments,
the kits can further comprise instructions for the use thereof.
In certain embodiments, the invention provides kits for
preparing a restricted access media comprising: i) a Support
that is Substantially free of ligand binding agent or enzyme
molecules, and ii) a capping agent. In certain embodiments,
the kits can further comprise any one of: 1) a solution for
activating the capping agent; 2) a Solution for activating said
support; 3) instructions for the use thereof; 4) an activated
Support; 5) aligand binding agent oran enzyme molecule that
is not associated with the Support; or any combination of
elements 1,2,3,4, and/or 5. In certain embodiments of any of
the foregoing kit embodiments, the restricted access media
that is prepared can comprise a Support wherein a plurality of
protected regions of the Support contain one or more unbound
ligand binding agent(s) or enzyme molecule(s) and wherein
the ligand binding agent(s) or enzyme molecule(s) are
retained in the protected regions by a capping agent.
In certain embodiments, the invention provides kits com
prising a restricted access media comprising: i) a Support
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wherein a plurality of protected regions of the Support contain
one or more unbound ligand binding agent or enzyme mol
ecules and wherein the ligand binding agent(s) or enzyme
molecules are retained in the protected regions by a capping
agent, and ii) at least one container. In certain embodiments,
the kits can further comprise instructions for the use thereof.
BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an illustration showing the preparation of a

10

Restricted Access Medium.

FIG. 2 is an illustration showing the structure of antibodies
located in protected and unprotected regions of the Support
before and after enzyme treatment for (a) the hydrazide
activated Support method and (b) the aldehyde-activated Sup
port method.
FIG. 3 is an illustration showing the structure of an IgG
antibody before and after papain or pepsin treatment.
FIG. 4(a) is bar graph showing the amount of covalently
linked antibody versus nominal pore size of the Support
before and after cleaving agent treatment.
FIG. 4(b) is bar graph showing the percentage of F,
regions remaining versus nominal pore size of the Support.
FIG. 5 is a line graph showing the amount of antibody
remaining after cleaving agent treatment.
FIG. 6 is a line graph showing the effect of cleaving agent
concentration on the amount of F, and antibody remaining
following treatment with cleaving agent.
FIG. 7 are chromatograms showing (a) fluorescein reten
tion by an anti-fluorescein RAM column and a control col
umn and (b) fluorescein-bovine serum albumin (BSA) reten
tion by an anti-fluorescein RAM column and a control

15
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that access to the contained molecules is restricted to mol
30

column.

FIG. 8 shows the percent extraction of fluorescein or fluo
rescein-BSA by an anti-fluorescein RAM.
FIG. 9 is an illustration showing (a) reaction between oxi
dized glycogen as the capping agent and a hydrazide-acti
vated Support and (b) retention of a protein as oxidized gly
cogen as the capping agent reacts with the hydrazide
activated Support.
FIG. 10 is a graph showing the amount of human serum
albumin (HSA) retained using a hydrazide-activated Support

35

40

with pore sizes ranging from 50 A to 1000 A.
DETAILED DESCRIPTION
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Definitions

As used herein, the phrase “ligand binding agent
molecule(s) refers to one or more molecules that can seques
ter another molecule or “target” from a solution. Ligand bind
ing agent molecules include, but are not limited to, a protein,
a glycoprotein, a DNA, a RNA, a nucleoprotein, or a carbo
hydrate-containing agent.
The terms “protein,” “peptide.” and “polypeptide' are used
interchangeably herein to refer to a polymer of amino acid
residues of any length.
As used herein, the phrase “blocking agent molecule(s)
refers to a molecule that is covalently linked to a support to
create a protected region in or upon the Support. A blocking
agent molecule can include, but is not limited to, a cleaved
Sub-fragment of a ligand binding agent molecule resulting
from treatment with a cleaving agent, leaving only a Sub
fragment of the ligand binding agent molecule covalently
linked to a Support. In certain embodiments, the Sub-fragment
of the ligand binding agent molecule that is linked to the
Support following cleavage is a Sub-fragment where ligand

6
binding activity is reduced. In certain embodiments, the Sub
fragment of the ligand binding agent molecule that is linked to
the Support following cleavage is a Sub-fragment where
ligand binding activity is eliminated. In still other embodi
ments, the Sub-fragment of the ligand binding agent molecule
that is linked to the Support following cleavage is a Sub
fragment wherealigand binding domain has been removed or
has been disrupted. In certain embodiments, the Sub-fragment
of the ligand binding agent molecule that is linked to the
Support following cleavage can be further modified using a
chemical reagent or second binding agent to reduce non
specific binding. In other embodiments, a blocking agent
molecule can be a different molecule than the ligand binding
agent molecule. In certain embodiments where the blocking
agent molecule is different than the ligand binding agent
molecule, the blocking agent molecule can be a Sub-fragment
of a linking agent. As used herein, a “linking agent” refers to
a molecule that is conjugated to the ligand binding agent
molecule and is used to attach the ligand binding agent mol
ecule to the Support. Linking agents include, but are not
limited to, carbohydrates, nucleic acids, and peptides.
As used herein, the phrase “capping agent” refers to a
molecule that is used to retain an unbound ligand binding
agent or enzyme in a protected region.
As used herein, the phrase “protected region” refers to an
area or space of a Support that contains either one or more
ligand binding agent molecule(s) or enzyme molecules Such
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ecules within a desired molecular weight range. A "protected
region' includes, but is not limited to, a pore, a space, a gap,
an opening, a hole, a crack, a fissure, a cavity, a pit, a crater, a
cleft, a crevice, or combinations thereof.
As used herein, the phrase “unprotected region” refers to
an area or space of a Support that is large enough to be
accessible by a cleaving agent. In the context of a RAM media
comprising one or more covalently linked ligand binding
agent molecule(s) in a protected region, a region occupied by
one or more blocking agent molecule(s) following enzyme or
protease treatment would represent an “unprotected region.”
In the case where the ligand binding agent molecule is an
antibody that is covalently linked to the support by its F.
region, for example, the cleaved F portion of the antibody
molecule that remains following cleaving agent treatment
resides in an “unprotected region'.
As used herein, the phrases “covalently linked and “cova
lent linkage” mean attached by a covalent bond. For example,
an antibody can be covalently linked to an aldehyde-activated
Support by amine linkages between the antibody and the
aldehyde-activated Support.
As used herein, the term "conjugated” means joined
together. Conjugation includes covalent linkages. For
example, a linking agent can be conjugated to, or joined
together with, a ligand binding agent molecule.
As used herein, the phrase “substantially free' refers to a
composition wherein the undesired material is present at a
final percent (i.e. weight undesired material/total composi
tion weight) of at least less than about 1%.
Restricted Access Media Comprising Protected Covalently
Linked Ligand Binding Agents
Certain embodiments of the invention include restricted

access media comprising a Support wherein a plurality of
protected regions of the Support contain one or more
covalently linked ligand binding agent molecule(s) and
wherein a plurality of unprotected regions of the Support
contain one or more covalently linked blocking agent mol
ecule(s). The Support can be any Support that can be used
directly or in a modified form for ligand binding agent attach
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ment and combinations thereof. In certain embodiments, Sup
ports can comprise an inorganic Support material. Inorganic
Support materials can include, but are not limited to, silica,
glass, alumina, Zirconia, silver, and gold. In certain embodi
ments, Supports can comprise a biological Support material.
Biological Support materials can include, but are not limited
to, agarose, dextran, and cellulose. Supports can comprise
one or more organic Support material(s) and organic polymer
Supports. Organic Support materials and organic polymer
Supports can include, but are not limited to, polystyrene,
polymethacrylate, and polyamide. In other embodiments, the
Support can comprise a composite Support. Composite Sup
ports include, but are not limited to, an agarose coating on
quartz, an agarose coating on stainless steel, and coated poly
styrene/divinylbenzene. In other embodiments, the support
can comprise a modified Support. Modified Supports can
include, but are not limited to, silica, glass beads, polystyrene,
gold, or silver that contain an added chemical group. Chemi
cal groups used in modified Supports include, but are not
limited to, Surface diol groups, aldehyde groups, hydrazide
groups, amine groups, and Sulfhydryl groups. Formats for the
Support can comprise porous or non-porous particles, planar
surfaces, or flow-through supports. Other formats for the
Support can include, but are not limited to, monolithic mate
rials or perfusion Supports, membrane Supports, capillaries,
fibers, and expanded bed Supports.
The ligand binding agent molecule can be a protein, a
glycoprotein, a DNA, a RNA, a nucleoprotein, or a carbohy
drate-containing agent. Without seeking to be limited by
theory, a size-restricted cleaving agent, such as an enzyme,
protease, or other agent, is unable to access the ligand binding
agent molecule residing in protected regions. While again not
seeking to be limited by theory, access of the size restricted
cleaving agent can be restricted by electrostatic and/or steric
hindrance. Thus, the size restricted cleaving agent cannot
cleave the ligand binding agent molecule, leaving it
uncleaved or intact. For example, the ligand binding agent
molecule can be an antibody. As shown in FIG. 1(a) using an
IgG antibody as the ligand binding agent molecule, the anti
body is covalently linked to the support by the F regions.
Upon treatment with an enzyme capable of cleaving away F,
regions, the enzyme is inaccessible to the antibody
molecule(s) residing in protected regions or excluded from
the protected regions. Thus, the enzyme or protease cannot
cleave antibody molecules residing in the protected regions,
leaving those molecules uncleaved or intact.
A blocking agent molecule can be a Sub-fragment of the
ligand binding agent molecule. The blocking agent molecule
can also be a Sub-fragment of a linking agent. In certain
embodiments, a linking agent is conjugated to the ligand
binding agent molecule and is used to attach the ligand bind
ing agent molecule to the Support. Linking agents include, but
are not limited to, carbohydrates, nucleic acids, and peptides.
In an exemplary embodiment, a nucleic acid linking agent
can be conjugated to a ligand binding agent that can be a
protein, a carbohydrate, or another nucleic acid. The nucleic
acid linking agent—ligand binding agent conjugate can then
be covalently linked to the support by the nucleic acid linking
agent. The nucleic acid is then cleaved with a size restricted
cleaving agent. The size restricted cleaving agent can be, for
example, an enzyme such as a nuclease. When the ligand
binding agent is also a nucleic acid, the nuclease can in certain
embodiments be a site specific nuclease that selectively
cleaves the nucleic acid linking agent. In this embodiment,
the remaining Sub-fragment of the nucleic acid that is linked
to the Support following nuclease cleavage is the blocking
agent.
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In another exemplary embodiment, a carbohydrate linking
agent can be conjugated to a ligand binding agent that can be
a protein or a nucleic acid. The carbohydrate protein con
jugate can then be covalently linked to the Support by the
carbohydrate linking agent. The carbohydrate is then cleaved
by a size restricted cleaving agent. The size restricted cleav
ing agent can be, for example, an enzyme that cleaves the
carbohydrate. In this embodiment, the remaining Sub-frag
ment of the carbohydrate linking agent that is linked to the
Support following cleavage is the blocking agent.
In yet another exemplary embodiment, a peptide linking
agent can be conjugated to the ligand binding agent that can
be a nucleic acid, a carbohydrate, or another protein. The
peptide linking agent—ligand binding agent conjugate can
then be covalently linked to the support by the peptide linking
agent. The peptide is then cleaved with a size restricted cleav
ing agent. The size restricted cleaving agent can be, for
example, a protease or peptidase. When the ligand binding
agent is also a protein, the protease or peptidase can in certain
embodiments be a site specific protease or peptidase that
selectively cleaves the peptide linking agent. In this embodi
ment, the remaining Sub-fragment of the peptide that is linked
to the Support following cleavage is the blocking agent.
As described, the ligand binding agent can be attached
either directly to the support or can be attached to the support
with a linking agent. Without seeking to be limited by theory,
the size restricted cleaving agent is able to access the ligand
binding agent molecule or linking agent residing in or on
unprotected regions and that is linked either directly or
through a linking agent to the unprotected regions of the
Support. Thus, the size restricted cleaving agent cleaves the
ligand binding agent molecule or linking agent. The sub
fragment of the cleaved ligand binding agent or linking agent
that is covalently linked to the support forms the blocking
agent molecule(s), whereby the fragment of the cleaved
ligand binding agent or linking agent—ligand binding agent
conjugate that is not covalently linked or is otherwise
unbound to the Support is removed. As shown in the non
limiting and exemplary embodiment depicted in FIG. 1(a).
when using an IgG antibody as the ligand binding agent
molecule, the antibody can be covalently linked to the support
by the F regions. Upon treatment with an enzyme capable of
cleaving away F, regions, the F. Sub-fragments of the anti
body are cleaved from the antibody molecules residing in or
on unprotected regions of the Support. The F region of the
antibody molecule that is covalently linked to the support
remains following enzyme treatment and forms the blocking
agent molecule.
Methods for Preparing a Restricted Access Media Compris
ing Protected Covalently Linked Ligand Binding Agents
Other embodiments of the invention include methods for
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preparing a restricted access media. Methods provided herein
comprise incubating an activated Support with a solution hav
ing a plurality of ligand binding agent molecules to form a
ligand bound Support wherein the ligand binding agent mol
ecule is covalently linked to the support. The ligand bound
Support is treated with a size restricted cleaving agent that
cleaves one or more ligand binding agent molecule(s) bound
to unprotected regions of the Support. The cleaving agent and
unbound fragments of cleaved ligand binding agent mol
ecules are removed, thereby preparing the restricted access
media.
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The ligand binding agent molecule can be a protein, a
glycoprotein, a DNA, a RNA, a nucleoprotein, or a carbohy
drate-containing agent. The ligand binding agent molecule
can be, for example, an antibody. Alternatively, the ligand
binding agent can be an aptamer or a lectin.
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The ligand binding agent molecule(s) can be covalently
linked to the Support by an amine group, a Sulfhydryl group,
a carboxylate group, a carbonyl group, or a combination
thereof. The ligand binding agent molecule(s) can also be
activated prior to incubation with the Support. For example, a
ligand binding agent molecule having carbohydrate residues
can be activated by oxidization of the carbohydrate residues.
Activation by oxidization can be performed by treatment of
the ligand binding agent molecule(s) with periodic acid, a
periodate-related chemical, or an enzyme treatment. In other
embodiments, the plurality of ligand binding agent molecules
can comprise ligand binding agent molecules that are conju
gated linking agents. In this embodiment, ligand binding
agent molecules can be covalently linked to the Support by a
linking agent. Linking agents can be carbohydrates, nucleic
acids, and peptides that can be attached to the Support.
The activated Support used in the method can be any Sup
port that can be used directly or in a modified form for ligand
binding agent attachment and combinations thereof. The Sup
port can be, for example, inorganic Support materials. Inor
ganic Support materials can be, for example, silica, glass,
alumina, Zirconia, silver, and gold. The Support also can be
biological Support materials. Biological Support materials
can be, for example, agarose, dextran, and cellulose. The
Support further can be organic Support materials and organic
polymer Supports. Organic Support materials and organic
polymer Supports can be, for example, polystyrene, poly
methacrylate, and polyamide. The Support can be composite
Supports. Composite Supports can be, for example, agarose
coating on quartz, agarose coating on stainless steel, and
coated polystyrene? divinylbenzene. Modified supports can
be, for example, silica, glass beads, polystyrene, gold, or
silver that contain, for example, Surface diol groups, aldehyde
groups, hydrazide groups, amine groups, and Sulfhydryl
groups. Formats for the Support can comprise porous or non
porous particles, planar Surfaces, or flow-through Supports.
Other formats for the support can include, but are not limited
to, monolithic materials or perfusion Supports, membrane
Supports, capillaries, fibers, and expanded bed Supports. An
activated Support can be an aldehyde-activated Support or a
hydrazide-activated Support.
An aldehyde-activated Support can be prepared according
to a method adapted from Larsson (104 Methods Enzymol.
212-223 (1984)) and Ruhn et al., (669 J. Chromatogr. 9-19
(1994)). Briefly, for example, an aldehyde-activated support
can be prepared by treating a porous silica Support with a
Solution comprising an organic silane Such as, 3-glycidox
ypropyltrimethoxysilane, to introduce epoxy groups onto the
Support. The resulting epoxy groups are hydrolyzed by treat
ing the Support with a sodium acetate Solution. After washing
with water, the Support is treated with an aqueous Solution of
Sulfuric acid to convert epoxy groups to diol groups. The
resulting diol support is treated with a solution of 90% (v/v)
acetic acid and water containing 500 mg periodic acid and
mixed for about two hours at room temperature to convert diol
groups to aldehyde groups. The resulting aldehyde-activated
support is washed with water followed by washing with a
potassium phosphate buffer and stored until use.
To prepare a hydrazide-activated Support, an aldehyde
activated Support is treated with a potassium phosphate buffer
containing about a 5-fold mole excess of Oxalic dihydrazide
(calculated using the initial diol groups present in the added
Support) with shaking for about 2 hours at room temperature.
After several potassium phosphate buffer washes, about a
25-fold mole excess (calculated using the initial diol groups)
of sodium borohydride in 0.1 M potassium phosphate buff
ered saline (PBS) is added in small portions to the slurry and
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incubated with shaking for about 90 minutes at room tem
perature to reduce any remaining aldehyde groups. The Sup
port is Subsequently washed in potassium phosphate buffer
and stored until use.
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To form the ligand bound support wherein the ligand bind
ing agent molecule is covalently linked to the Support, an
activated Support is treated with a solution comprising a
ligand binding agent molecule(s) to form a slurry. The
amount of ligand binding agent molecule(s) used can be
greater than the maximum amount that can be immobilized
on the Surface of the Support and based on the Surface area of
the Support and size of the ligand binding agent molecule(s).
For example, if the ligand binding agent molecule is an IgG
antibody, the amount used is about two-fold greater than the
maximum amount that can be immobilized to the Surface of

the support, as determined by Clarket al., (888.J. Chromatog.
13-22 (2000)) and by calculations based on the known surface
area of the support and size of IgG (see e.g., Walters etal. (140
Anal. Biochem. 190-195 (2000)). When an aldehyde-acti
vated Support is used, a solution Such as an 8 mg/mL Sodium
cyanoborohydride solution, can be added to the slurry to
promote formation of stable secondary amine linkages
between the ligand binding agent molecule(s) and the Sup
port. When a hydrazide-activated Support is used, the ligand
binding agent molecule can be activated prior to addition to
the Support. When the ligand binding agent molecule is an
IgG antibody for example, the antibody can be activated by
oxidization with periodate to generate aldehyde groups in the
carbohydrate regions. Preferably, cross-linked or precipitated
immunoglobulins are removed from the final oxidized anti
body solution prior to incubation with the activated support.
The activated support and ligand binding agent molecule
slurry is incubated while shaking for 3 days at 4°C. The
resulting Support is washed with about 0.1 M potassium phos
phate buffer (pH 8.0) and treated with a 4 mg/mL solution of
sodium borohydride for about 90 minutes at room tempera
ture to convert any remaining aldehyde groups into alcohols.
A ligand bound Support obtained by any of the methods
provided herein or elsewhere is treated with a size restricted
cleaving agent to produce the restricted access media in
which protected regions of the Support contain uncleaved
ligand binding agent molecule(s) and unprotected regions of
the Support contain cleaved ligand binding agent molecule(s).
Without seeking to be limited by theory, some of the ligand
binding agent molecule(s) within protected regions of the
support will be inaccessible to the cleaving agent. This will
leave ligand binding agent molecules residing in protected
regions intact, while ligand binding agent molecules residing
in unprotected regions of the support will be cleaved. For
example, using an IgG antibody as the ligand binding agent
molecule and an enzyme capable of cleaving away Fab
regions as the cleaving agent, antibody molecules residing in
unprotected regions are accessible to the enzyme and are
cleaved. Antibodies residing in protected regions, however,
are inaccessible to the enzyme and remain intact where they
can function to bind their target molecule (see, FIGS. 1(a) and
(b)). FIG. 2(b) is an illustration showing the structure of an
IgG antibody covalently linked to an aldehyde-activated Sup
port using the Schiff base method before and after cleaving
agent treatment. Antibody molecules residing within a pro
tected region Such as a pore remain intact following cleaving
agent treatment. Antibody molecules residing in an unpro
tected region Such as an outer Surface, are cleaved. Depending
on where the covalent linkage between the antibody molecule
and the Support occurs, either the F, or F. Sub-fragment
remains covalently attached to the Support following cleaving
agent treatment. In FIG. 2(b), the cleaved sub-fragments rep
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resenting the F, and F regions of the antibody form the
blocking agent molecule(s). FIG. 2(a) is an illustration show
ing the structure of an IgG antibody covalently linked to a
hydrazide-activated Support before and after cleaving agent
treatment. Antibody molecules residing within a protected
region Such as a pore remain intact following cleaving agent
treatment. Antibody molecules residing in an unprotected
region Such as an outer Surface, are cleaved. Because the
antibody molecule is covalently linked to the hydrazide-acti
vated Support by the F region, only the Sub-fragment repre
senting the Fregion remains covalently linked to the Support
and forms the blocking agent molecule(s) in this illustration.
The size restricted cleaving agent can be a lyase or hydro
lase. For example, the size restricted cleaving agent can be an
enzyme or ribozyme. The size restricted cleaving agent can
also be, for example, a protease (also referred to herein inter
changeably with the term "peptidase). Proteases that can be
used include, but are not limited to, cysteine proteases, serine
proteases, threonine proteases, aspartate proteases, and met
alloproteases. Proteases that can be used as size restricted
cleaving agents can also include, but are not limited to,
trypsin, elastase, papain, pepsin, ficin, Lys-C, or Glu-C.
Several criteria can be considered when selecting the size
restricted cleaving agent. In certain embodiments, a size
restricted cleaving agent able to digest the ligand binding
agent molecule at well-defined sites and that leaves the bind
ing regions largely intact can be used. In certain embodi
ments, a size restricted cleaving agent that cleaves the ligand
binding agent molecule into only a few large fragments can be
used. The size restricted cleaving agent should also be large
enough that it is excluded from the protected regions of the
support such that ligand binding agent molecules residing in
protected regions are not cleaved. The size restricted cleaving
agent can be of similar size or larger than any proteins or
molecules that are to be excluded from the protected region

12
The size of the protected region can vary if exclusion of
Smaller or larger sample components is desired. When the
ligand binding agent molecule is an IgG antibody, for
example, the size of the protected region of the Support can be
5

amount of covalently linked IgG using porous silica as the
Support. The total amount of bound IgG increased when pore
size increased from 50 A to 300A and decreased between 300
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Activity of the size-restricted cleaving agent can also be
modulated through control of a number of variables. Relevant
variables that can be manipulated to control cleaving agent
activity include, but are not limited to, temperature, pH, ionic
strength, concentration of any required cations or anions,
concentration of any required cofactors, time of treatment,
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and/or various combinations of these variables. Time of treat

ment with the size restricted cleaving agent can affect the
amount of ligand binding agent molecules remaining on the
support. For example, FIG. 5 shows the effect of time on the
amount of antibody remaining after treatment using an anti
body as the ligand binding agent molecule and papain as the
size restricted cleaving agent.
To perform the cleavage treatment, the Support is treated
with a solution comprising a size restricted cleaving agent.
The cleavage treatment can be stopped by removal of the
cleavage agent and/or by addition of an inhibitor. Inhibitors
can be cysteine protease inhibitors, serine protease inhibitors,
threonine protease inhibitors, aspartic protease inhibitors,
metalloprotease inhibitors. For example, iodoacetamide can
be used to stop the cleavage treatment with papain. Soybean
trypsin inhibitor, lima bean trypsin inhibitor, Kunitz inhibitor,
serum trypsin inhibitor, and ovomucoid trypsin inhibitor, for
example, can be used to stop the cleavage treatment with
trypsin. Pepstatin can be used to stop the cleavage treatment
with pepsin. Additional cleaving agent inhibitors will be
readily recognized by those skilled in the art. The cleavage
treatment can also be stopped by washing the Support with
phosphate buffered saline and water to remove the cleavage
agent and any fragments of the ligand binding agent molecule
that are cleaved from the support.

about 50 A to about 500 A and preferably is about 100 A to
about 300 A. FIG. 4 shows the effect of pore size on the total
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A and 500 A. FIG. 4(b) further indicates in examples using

porous silica that pore size can affect accessibility by the
cleaving agent.
The resulting RAM comprising protected covalently
linked ligand binding agents can be used in a variety of
applications that provide for target molecule purification or
target molecule analysis. It is believed that this RAM com
prising protected covalently linked ligand binding agents can
be used for analytical chromatography, column chromato
graph, batch chromatography, or biosensors.
Restricted Access Medium comprising Unbound Ligand
Binding Agents or Enzymes in Protected Regions
Other embodiments of the invention provided herein are
restricted access media comprising a Support wherein a plu
rality of protected regions of the Support contain one or more
unbound ligand binding agent(s) or enzyme molecules and
wherein the ligand binding agent(s) or enzyme molecule(s)
are retained in the protected regions by a capping agent. The
protected region of the Support can be on a Surface, in a pore,
or a combination of Surfaces and pores. The Support can be
any support familiar to those skilled in the art that can be used
directly or in a modified form for ligand binding agent attach
ment and combinations thereof. The support can be, for
example, inorganic Support materials. Inorganic Support
materials can be, for example, silica, glass, alumina, Zirconia,
silver, and gold. The Support also can be biological Support
materials. Biological Support materials can be, for example,
agarose, dextran, and cellulose. The Support further can be
organic Support materials and organic polymer Supports.
Organic Support materials and organic polymer Supports can
be, for example, polystyrene, polymethacrylate, and polya
mide. The Support can be composite Supports. Composite
Supports can be, for example, agarose coating on quartz,
agarose coating on stainless steel, and coated polystyrene?
divinylbenzene. Modified supports can be, for example,
silica, glass beads, polystyrene, gold, or silver that contain,
for example, Surface diol groups, aldehyde groups, hydrazide
groups, amine groups, and Sulfhydryl groups. Formats for the
Support can comprise porous or non-porous particles, planar
surfaces, or flow-through supports. Other formats for the
Support can include, but are not limited to, monolithic mate
rials or perfusion Supports, membrane Supports, capillaries,
fibers, and expanded bed supports. The unbound ligand bind
ing agent can be a protein, a glycoprotein, a DNA, a RNA, a
nucleoprotein, a carbohydrate-containing agent, a lipopro
tein, or related agents. The DNA-based or RNA-based ligand
binding agent can be an aptamer. Enzymes used in the RAM
include, but are not limited to, glucose oxidase, horseradish
peroxidase, and other enzymes that act on Small Substrates
that can enter and leave the protected regions. Other enzymes
used in the RAM can include, but are not limited to, that
oxidoreductases, transferases, hydrolases, lyases,

isomerases, and ligases. The capping agent can be a glyco
protein, a glycolipid, a carbohydrate-containing agent, or a
combination of different capping agents. Related agents
include, but are not limited to, a protein-protein complex, a
protein-DNA complex, and a protein-RNA complex. Carbo
hydrate-containing agents include, but are not limited to,
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polysaccharides. Polysaccharides can include, but are not
limited to, glycogen, dextran, agarose, and cellulose.
RAM provided herein thus comprise media where a ligand
binding agent or enzyme is retained in a protected region in an
unbound form. Without seeking to be limited by theory, RAM
comprising unbound ligand binding agents or enzymes pro
vide for presentation of the ligand binding agents or enzymes
in a native or near-native form. In contrast, covalent linkage of
a ligand binding agent to a Support may decrease ligand
binding agent activity and/or ligand binding agent specificity.
Similarly, covalent linkage of an enzyme to a Support may
decrease enzymatic activity. Moreover, an unbound ligand
binding agent or enzyme will respectively encounter a target
molecule or Substrate at a faster rate than a bound ligand
binding agent or enzyme.
Method for Preparing Restricted Access Medium comprising
Unbound Ligand Binding Agents or Enzymes in Protected
Regions
Various methods for preparing Restricted Access Medium
comprising unbound ligand binding agents or enzymes in
protected regions are provided herein. In certain embodi
ments, methods for preparing a restricted access media com
prising incubating an activated Support with a solution com
prising i) a ligand binding agent or an enzyme molecule and
ii) an activated capping agent; and removing unbound cap
ping agent from the incubated Support, thereby preparing the
restricted access media comprising a Support wherein a plu
rality of protected regions of the Support contain one or more
unbound ligand binding agent(s) or enzyme molecule(s) and
wherein the ligand binding agent(s) or enzyme molecule(s)
are retained in the protected regions by the capping agent are
provided.
Methods provided herein can further comprise washing the
restricted access media with a solution to deactivate bound

capping agent. Solutions to deactivate bound capping agent
include, but are not limited to, a hydrazide-containing agent,
an amine-containing agent, and a hydrazine-containing
agent. For example, the hydrazide-containing agent oramine
containing agent can be oxalic dihydrazide adipic dihy
drazide, Succinic dihydrazide, ethanolamine, and ethylamine.
The activated Support can be any support that can be used
directly or in a modified form for ligand binding agent attach
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ment and combinations thereof. In certain embodiments, acti

vated Supports can comprise inorganic Support materials.
Inorganic Support materials can include, but are not limited
to, silica, glass, alumina, Zirconia, silver, and gold. In certain
embodiments, activated Supports can comprise biological
Support materials. Biological Support materials can include,
but are not limited to, agarose, dextran, and cellulose. Acti
vated Supports can comprise one or more organic Support
material(s) and organic polymer Supports. Organic Support
materials and organic polymer Supports can include, but are
not limited to, polystyrene, polymethacrylate, and/or polya
mide. In other embodiments, the activated Support can com
prise composite Supports. Composite Supports include, but
are not limited to, an agarose coating on quartz, an agarose
coating on stainless steel, and coated polystyrene? divinylben
Zene. In other embodiments, the activated Support can com
prise modified Supports. Modified supports can include, but
are not limited to, silica, glass beads, polystyrene, gold, or
silver that contain an added chemical group. Chemical groups
used in modified Supports include, but are not limited to,
Surface diol groups, aldehyde groups, hydrazide groups,
amine groups, and Sulfhydryl groups. The hydrazide group,
an amine group, an aldehyde group, or a combination of
hydrazide groups, amine groups, and/or aldehyde groups of
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the activated Support can be activated to permit covalent
binding of a ligand binding agent or linking agent.
The unbound ligand binding agentorenzyme molecule can
be a protein, a glycoprotein, a DNA, a RNA, a nucleoprotein,
a carbohydrate containing agent, a lipoprotein, or related
agents. Related agents include, but are not limited to, a pro
tein-protein complex, a protein-DNA complex, and a protein
RNA complex. The unbound ligand binding agent or enzyme
molecule and activated capping agent can be incubated
together or separately with the activated Support.
The activated capping agent can be a glycoprotein, a gly
colipid, or a carbohydrate-containing agent. Carbohydrate
containing agents include, but are not limited to, polysaccha
rides. Polysaccharides include, but are not limited to,
glycogen, dextran, agarose, and cellulose. The activated cap
ping agent can be activated by oxidization with an oxidizing
agent. Oxidizing agents can include, but are not limited to,
periodate, a periodate-related chemical, or an enzyme treat
ment. The periodate can include, but is not limited to, Sodium
periodate, potassium periodate, or periodic acid. The acti
vated capping agent can be an oxidized capping agent. For
example, the oxidized capping agent can be an oxidized gly
coprotein, a oxidized glycolipid, or an oxidized carbohy
drate-containing agent. Oxidized carbohydrate-containing
agents include, but are not limited to, oxidized glycogen,
oxidized dextran, oxidized agarose, or oxidized cellulose.
Without seeking to be limited by theory, when the oxidized
capping agent is incubated with the activated Support, groups
of the oxidized capping agent such as aldehyde groups, form
covalent bonds with groups of the Support such as hydrazide
groups. Thus, the capping agent retains the ligand binding
agent or enzyme molecule(s) present in the reaction mixture.
FIG. 9 is an illustration showing retention of a protein using
oxidized glycogen as the capping agent and a hydrazide
activated Support.
After retaining the ligand binding agent or enzyme mol
ecule(s), the resulting restricted access media can be used for
measuring the activity of the retained ligand binding agent or
enzyme molecule(s) and/or placed into columns for uses Such
as high performance affinity chromatography, Solid-phase
immunoassays, and immobilized enzyme reactors.
The resulting RAM comprising protected unbound ligand
binding agents can be used in a variety of applications that
provide for target molecule purification or target molecule
analysis. It is believed that this RAM comprising protected
unbound ligand binding agents can be used for analytical
chromatography, column chromatography, batch chromatog
raphy, or biosensors.
The resulting RAM comprising protected unbound
enzymes can be used in a variety of applications that provide
for conversion of substrates to products. These applications of
RAM comprising protected unbound enzymes include both
analytic and preparative uses. It is anticipated that this RAM
comprising protected unbound enzymes are especially useful
in applications where it is desirable to sequester the enzyme
from the sample containing the Substrate.
Kits for Preparing a Restricted Access Media
Other embodiments of the invention are kits for preparing
a restricted access media comprising: i) a Support that is
Substantially free of ligand binding agent molecules and ii) a
size restricted cleaving agent. The kits can further comprise
instructions for using the kit. The kits can also comprise an
activated Support or an unactivated Support. The kits can also
comprise a solution for activating the Support. The kits can
further comprise a ligand binding agent, a linking agent,
and/or an enzyme molecule that is not covalently linked to the
Support. The restricted access media that is prepared using the
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kits can comprise a Support wherein a plurality of protected
regions of the Support contain one or more covalently linked
ligand binding agent molecules and wherein a plurality of
unprotected regions of the Support contain one or more
covalently linked blocking agent molecule(s).
In other embodiments, kits comprising a restricted access
media comprising: i) a Support wherein a plurality of pro
tected regions of the Support contain one or more covalently
linked ligand binding agent molecules and whereina plurality
of unprotected regions of the Support contain one or more
covalently linked blocking agent molecule(s) and ii) at least
one container are provided. The kits can further comprise
instructions for using the kit.
In still other embodiments of the invention, kits for prepar
ing a restricted access media comprising: i) a Support that is
Substantially free of ligand binding agent or enzyme mol
ecules, and ii) a capping agent are provided. The kits can
further comprise a solution for activating the capping agent.
The kits can further comprise a solution for activating the
support. The kits can further comprise instructions for their
use. The kits can comprise an activated Support. The kits can
further comprise a ligand binding agent or an enzyme mol
ecule that is not associated with the Support. Restricted access
media that is prepared from the kit can comprise a Support
wherein a plurality of protected regions of the Support contain
one or more unbound ligand binding agent(s) or enzyme
molecule(s) and wherein the ligand binding agent(s) or
enzyme molecule(s) are retained in the protected regions by a
capping agent.
Other embodiments of the invention are kits comprising a
restricted access media comprising: i) a Support wherein a
plurality of protected regions of the support contain one or
more unbound ligand binding agent or enzyme molecules and
wherein the ligand binding agent(s) or enzyme molecules are
retained in the protected regions by a capping agent, and ii) at
least one container. The kits can further comprise instructions
for using the kit.
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Description of Chemicals and Apparatus
Nucleosil Si-50, Si-100, Si-300 and Si-500 silica supports
(7 um particle diameter; nominal pore size, 50, 100, 300 or

A silica Support was converted into a diol form by treating
a 500 mg quantity of the Support with 3-glycidoxypropyltri
methoxysilane to introduce epoxy groups onto the silica. The
resulting epoxy silica support was treated with 0.1 M sodium
acetate buffer at pH 5.5 by sonication under vacuum for 10-15
minutes. 3-Glycidoxypropyltrimethoxysilane (5%-10% V/v)
was added into the suspension and shaken for 5 hours at 90°
C. The epoxy silica support was washed several times with
water and an aqueous solution of sulfuric acid (pH 3.0). The
epoxy silica support was then suspended in 100-150 mL of an
aqueous sulfuric acid solution (pH 3.0) and refluxed for one
hour to convert the epoxy silica support into a diol form. The
resulting diol silica Support was washed with several portions
of water, methanol and ether. The diol silica support was dried
overnight under vacuum and stored in a desiccator until use.
The diol content of the diol silica support was determined
using an iodometric capillary electrophoresis assay.
To convert the diol groups to aldehyde groups, 500 mg of
the diol silica support was suspended in 10 mL of a 90% (v/v)
mixture of acetic acid and water that contained 500 mg peri
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odic acid. The mixture was sonicated under vacuum for 20
minutes and shaken on a wrist-action shaker for 2 hours at
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room temperature. The resulting aldehyde-activated silica
was washed several times with water and, 0.10M potassium
phosphate buffer (pH 6.0). The aldehyde-activated silica Sup
port was used directly for preparing a restricted access media
or for preparing a hydrazide-activated silica Support.

500 A, respectively) were from Macherey Nagel (Düren,

Germany). Rabbit immunoglobulin G (IgG, reagent grade),
monoclonal anti-fluorescein antibodies (anti-FITC clone FL
D6, produced in mouse ascites fluid), the fluorescein conju
gate of bovine serum albumin (fluorescein-BSA; prepared
using fluorescein isothiocyanate and giving 12 mol fluores
cein/mol protein), papain (85% protein, from papaya latex),
fluorescein (290% pure), periodic acid reagent (>99% pure),
sodium cyanoborohydride (>99% pure), sodium borohydride
(98% pure), D/L-dithiothreitol (DTT, >99% pure), iodoaceta
mide (-99% pure), and ethylenediaminetetraacetic acid diso
dium salt dehydrate (EDTA, -99% pure) were from Sigma

scan speed, medium; sensitivity, high. The buffers employed
in preparing samples were used to autoZero the spectrofluo
rometer before each analysis.
The RAM prepared using IgG antibody as the ligand bind
ing agent molecule and control columns were packed using a
Shimadzu LC-10AT pump and a Rheodyne 710 six-port valve
(Cotati, Calif.). The chromatographic system comprised a
Perkin Elmer Series 200 micropump (Norfolk, Conn.) and a
Shimadzu RF-525 fluorescence detector. Samples were
injected using a Rheodyne LabPro valve equipped with a 200
LL loop. Chromatographic data were collected and processed
using LabView 5.1 (National Instruments, Austin, Tex.).
Example 2

Preparation of Aldehyde-Activated Support

EXAMPLES

The following examples describe embodiments of the
invention. Other embodiments within the scope of the claims
herein will be apparent to one skilled in the art from consid
eration of the specification or practice of the invention as
disclosed herein. It is intended that the specification, together
with the examples, be considered exemplary only, with the
Scope and spirit of the invention being indicated by the claims
which follow the examples.
Example 1
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(St. Louis, Mo.). The 3-glycidoxypropyltrimethoxysilane
(>94% pure), and oxalic dihydrazide (98% pure) were from
Aldrich (Milwaukee, Wis.). Ethylene glycol (>99% pure) was
from Fisher Scientific (Pittsburgh, Pa.). The acetic acid
(>99.7% pure) was from EMD chemicals (Gibbstown, N.J.).
Reagents for the bicinchoninic acid (BCA) protein assay
were from Pierce (Rockford, Ill.). All aqueous solutions were
prepared using water from a Nanopure system (Barnstead,
Dubuque, Iowa) and were filtered using 0.22 um nylon filters
(Fisher Scientific).
Slide-A-Lyzer dialysis cassettes (7 kDa MW cutoff, 0.5-3
mL capacity) were from Pierce. BCA assays were performed
using a Shimadzu UV-160A spectrophotometer (Kyoto,
Japan). Fluorescence spectra were acquired with a Shimadzu
RF-5301 PC spectrofluorometer using the following settings:
excitation wavelength, 460 nmi; emission wavelengths, 300

Example 3
Preparation of Hydrazide-Activated Support
65

To prepare a hydrazide-activated silica Support, 200 mg of
the aldehyde-activated silica support was suspended in 30 mL
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of 0.10M potassium phosphate buffer (pH 5.0) that contained
a 5-fold mole excess of oxalic dihydrazide versus the initial
diol groups present in the added aldehyde-activated silica
Support. The slurry was shaken for 2 hours at room tempera
ture on a wrist-action shaker. The Support was then washed
several times with 0.10 M potassium phosphate buffer (pH
7.0). After activation, a 25-fold mol excess of sodium boro
hydride (versus the initial diol groups) in 4 mL of 0.10 M
potassium phosphate buffer (pH 8.0) was added in several
Small portions to the Support slurry to reduce any remaining
aldehyde groups. This mixture was shaken for 90 minutes at
room temperature and washed several times with 0.10 M
potassium phosphate buffer (pH 7.0). The final hydrazide
activated support was stored in 0.10M potassium phosphate
buffer (pH 7.0) at 4°C. until use.
Example 4
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Preparation of RAM Using IgG Antibody Covalently
Linked According to an Aldehyde-Activation (Schiff
Base) Method
Rabbit IgG was used without pretreatment. A 13 mg/mL
slurry of aldehyde-activated silica (prepared as described in
Example 2) was sonicated under vacuum for 5 minutes in 0.10
M potassium phosphate buffer (pH 6.0). To this slurry was
added 0.69, 0.69, 0.20 or 0.069 mg antibody per mg of alde
hyde-activated Nucleosil Si-50, Si-100, Si-300 or Si-500
silica, respectively. Rabbit IgG amounts were at least two
fold greater than the maximum amount that could be immo
bilized to the surface of each support, as determined by Kim
et al., (In Handbook of Afinity Chromatography, Hage, D. S.,
ed. CRC Press: Boca Raton, Fla. (2006)) and calculations
based on the known Surface area of these Supports and the size
of IgG (see, Walters et al. (140 Anal. Biochem. 190-195
(1984)). About 8 mg/mL sodium cyanoborohydride was also
added to each reaction slurry to promote the formation of
stable secondary amine linkages between the retained anti
bodies and the support. The slurry was shaken for 3 days at 4
C. The resulting material was washed several times with 0.10
Mpotassium phosphate buffer (pH 8.0). The support was then
Suspended in 2 mL of a 4 mg/mL Solution of sodium borohy
dride in 0.10 M potassium phosphate buffer pH (8.0) to con
Vert any remaining aldehyde groups into alcohols. The mix
ture was shaken for 90 minutes at room temperature. The
resulting antibody restricted access medium was washed sev
eral times with water for later use in a BCA assay or dried
overnight under vacuum and stored in a desiccator for later
analysis.

25

Preparation of Immunoaffinity-Restricted Access
Media
30

35

Rabbit IgG and anti-fluorescein (monoclonal anti-FITC
clone FL-D6) antibodies to be covalently linked using the
hydrazide-activation method were oxidized with periodate to
generate aldehyde groups in their carbohydrate regions. To
oxidize rabbit IgG, 2 mg/mL of rabbit IgG was added to a
solution containing 20 mM sodium acetate and 0.15 M
sodium chloride (pH 5.5). To oxidize anti-fluorescein anti
bodies, the anti-fluorescein antibodies were exchanged into
20 mM sodium acetate and 0.15 M sodium chloride (pH 5.5)
buffer using Econo-Pac 10 DG desalting columns (BioRad;
Hercules, Calif.) at about 2 mg/mL final concentration. A 20

RAM prepared in Examples 4 and 5 were treated with a
size restricted cleaving agent to prepare immunoaffinity
restricted access media (“IA-RAM). In this example, papain
was used as the size restricted cleaving agent. The papain
Solution comprised 2 mg/mL papain in phosphate-buffered
saline (PBS; pH 7.5) containing 50 mM phosphate, 150 mM
sodium chloride, 2.7 mM potassium chloride, 2 mM EDTA
and 1 mM DTT. DTT was used to reduce disulfide bonds
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within papain for activation.
To perform the papain cleavage treatment, the desired
immunoaffinity Support (either aldehyde-activation method
or hydrazide-activation method) was washed twice with the
PBS (pH 7.5), suspended in PBS (pH 7.5) and sonicated for 5
minutes. The concentration of antibodies in the Solution was
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0.3-1.2 mg/mL. The papain solution was added to the slurry at
a papain:immunoglobulin ratio of 1:100 (w/w). The mixture
was incubated at 37°C. for 30 minutes. The papain treatment
was stopped by adding 30 mMiodoacetamide and incubating
in the dark for 60 minutes on ice. The papain-treated support

50

was washed several times with PBS and water to remove the

Example 5
Preparation of RAM Using IgG and Anti-Fluorescein
Antibodies Covalently Linked According to a
Hydrazide-Activation (Site-Selective) Method
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mM solution of periodic acid was made in the same buffer (20
mM sodium acetate containing 0.15 M sodium chloride, pH
5.5) and added to the antibody solutions in a 1:1 volume ratio.
The mixtures were protected from light exposure by wrap
ping the containers in aluminum foil and shaken for 30 min
utes at room temperature. The oxidation process was
quenched by adding 0.25 mL of ethylene glycol per mL of the
oxidized antibody solution and shaking an additional 5 min
utes at room temperature. Excess periodic acid was removed
from the oxidized antibody solution by dialysis in two hour
cycles against one 2 L portion of 20 mM sodium acetate and
0.15 M sodium chloride (pH 5.5) and three 2 L portions of
0.10 potassium phosphate buffer (pH 7.0). The final oxidized
antibody solution was passed through a 0.22 Lum filter to
remove any cross-linked or precipitated immunoglobulins.
The concentrations of the final antibody solutions were deter
mined to be 0.6-0.7 mg/mL by a BCA assay. Oxidized anti
body was combined with 4-5 mg hydrazide-activated silica
Supporting antibody and incubated in 0.10M potassium phos
phate buffer (pH 7.0) at 4°C. for 3 days. The supernatant was
collected and analyzed by a BCA assay. The Support contain
ing the covalently linked antibody was packed within a col
umn or washed several times with water and dried overnight
under vacuum for analysis by a BCA assay.
Example 6
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papain and any antibody fragments cleaved from the Support.
Supports to be examined by a BCA assay were dried over
night under vacuum and stored in a desiccator at room tem
perature. The anti-fluorescein support to be used in chromato
graphic studies was washed three times with 0.10 M
potassium phosphate buffer (pH 7.4) and stored in this buffer
at 4°C. until use.

60
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The anti-fluorescein IA-RAM support was packed into a
sandwich microcolumn according to Clark et al., (73 Anal.
Chem. 2157-2164 (2001)) and Clarke et al., (73 Anal. Chem.
1366-1373 (2001)). The column had an inner diameter of 2.1
mm and a total length of 1.0 cm, with a 2 mm long section in
the middle containing the anti-fluorescein IA-RAM support
while the remainder contained an inert layer of diol silica. The
Support was placed into the column by making fifty-three
200-uI, injections of a 0.32 mg/mL slurry of the anti-fluores
cein IA-RAM supportin 0.067 M potassium phosphate buffer
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(pH 7.0). A 2 mg/mL slurry of diol Nucleosil Si-100 in 0.067
M potassium phosphate buffer (pH 7.0) was used to fill the
remainder of the column. A control column was prepared in a
similar manner using diol silica in place of the IA-RAM
Support.

20
Example 8
Effect of Cleaving Agent Treatment Time
5

Example 7

FIG. 5 shows the results of varying the treatment time of
the cleaving agent. Rabbit IgG was covalently linked accord
ing to the aldehyde-activation (i.e., Schiffbase) method onto

a 100 A pore size silica support and treated with papain as the

Evaluation of IA-RAM Supports
The amount of polypeptides on an IA-RAM support before
or after treatment with papain was determined using a BCA
assay. The amount of antibodies/IgG placed on a Support by
the hydrazide-activation (site-selective) method was deter
mined by comparing the final and initial concentrations of the
antibodies/IgG in the Supernatant of the reaction slurry and/or
by directly measuring the final protein content of the Support.
The amount of antibodies/IgG remaining after papain treat
ment was determined by comparing the protein content of the
Support before and after papain treatment.
The binding properties of the anti-fluorescein IA-RAM
support were initially determined before and after digestion
by reacting this Support with a known excess of fluorescein
(sodium salt, MW=376 Da) or fluorescein-BSA conjugate
(average MW-69.5 kDa). Studies were performed using anti
fluorescein antibodies covalently linked to Nucleosil Si-100
using the hydrazide-activation method. A 2 mg portion of the
desired anti-fluorescein Support was incubated with shaking
in 1 mL of a 0.040 ug/mL fluorescein solution or 1 mL of 20
ug/mL fluorescein-BSA solution in 0.1 M potassium phos
phate buffer (pH 7.4) at 4°C. for 30 minutes. The mixtures
were centrifuged and the Supernatant was analyzed for fluo
rescein or fluorescein-BSA content based on the fluorescence
of the solutions. Standard solutions that contained 0.002-2.0

ug/mL fluorescein or 1-30 ug/mL of the fluorescein-BSA
conjugate in 0.10 M potassium phosphate buffer (pH 7.4)
were also analyzed. The amount of fluorescein or fluorescein
BSA bound to the anti-fluorescein IA-RAM supports was
determined by comparing the final and initial concentrations
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As the treatment time continued, however, the amount of

antibody remaining on the Support decreased only slightly
and approached a fixed value. These results indicate that all of
the accessible antibodies on the support had been cleaved by
papain. Similar results were observed in experiments using

300 A pore size silica supports.

Example 9
25

Effect of Cleaving Agent Concentration

30

35

40

45

50

amount of non-retained fluorescein or fluorescein-BSA was

monitored using an on-line fluorescence detector set at exci
tation and emission wavelengths of 488 and 520 nm, respec
tively. The fraction of extracted fluorescein was calculated by
comparing the areas of the non-retained peaks to those
obtained using a control column. Measurements made at 0.01
mL/min (i.e., an incubation time 10-fold longer than the
longest sample contact time used in the extraction study) were
used to correct the peak areas for any Small amount of non
binding, fluorescent contaminants that were present in the
samples. The retained species were eluted between studies by
washing the column with a 0.067 M potassium phosphate
buffer (pH 2.5) for 20 minutes. Elution was followed by a
column regeneration step by applying 0.067 M phosphate
application buffer (pH 7.4) for 10 minutes before each new
sample injection.

The concentration of cleaving agent added to the Support
for treatment (as reflected by the cleaving agent:antibody
ratio) can also control the amount of F, regions remaining on
the IA-RAM support after cleaving agent treatment. Without
being held to a particular theory, a low concentration of cleav
ing agent may lead to slow or incomplete digestion of anti
bodies while higher concentrations may lead to aggregation
or adsorption onto the Support. The effect of varying cleaving
agent:antibody ratio was examined using rabbit IgG that was
covalently linked using the hydrazide-activated Support

method onto a 100 A pore size silica support and treated with

of fluorescein or fluorescein-BSA that remained in solution.

For chromatographic Studies, 200LL injections of samples
containing 0.5 nM fluorescein or 3 nM of fluorescein-BSA
were made at flow rates ranging from 0.1-1.0 mL/min. The
injections were performed at room temperature using 0.067
M potassium phosphate buffer (pH 7.4) as the application
buffer. Two or three replicate injections were made at each
flow rate onto columns containing the anti-fluorescein IA
RAM Support or the corresponding control Support. The

cleaving agent. Antibodies covalently linked to this Support
were treated using an initial papain:antibody ratio of 1:100
(w/w), but the treatment time ranged from 0 to 6 hours.
As shown in FIG. 5, a sharp decrease in the amount of
antibody remained on the Support as the treatment time with
papain increased from 0 to 30 minutes. At 30 minutes, the
total antibody content had decreased to 36 (t2) mg/g Support,
which was 62 (+6)% of the antibody content before treatment.

papain for 3 hours. In this study the concentration of papain
used for digestion was varied from a papain:antibody ratio of
1:400 to 1:10 (w/w).
FIG. 6 shows a sharp decrease in the amount of antibody
left on IA-RAM supports after treatment with papain using
papain:antibody ratios of 1:400 to 1:100, or 0.0025 to 0.010
papain:IgG (w/w). Similar antibody contents were observed
after treatment of Supports using larger papain:antibody
ratios of 1:50-1:10, or 0.020-0.10 papain:IgG (w/w). There
fore, most of the accessible antibodies were cleaved by papain
within 3 hours using an papain:antibody ratio of 1:100 or
greater.

Example 10
55

Effect of Method for Covalently Linking IgG
Antibody

60

The effect of the method for covalently linking the anti
body was examined by covalently linking rabbit IgG using an
aldehyde-activated silica support (Schiff base) method or a
hydrazide-activated silica Support method. Supports with a

pore size of 100 A were treated with papain for 3 hours using

65

an papain:antibody ratio of 1:100. In the aldehyde-activated
silica support (Schiff base) method, the polypeptide content
of the support before and after treatment with papain was 58
(t4) or 33 (t2) mg/g silica, respectively.
In the hydrazide-activated Support method, the polypeptide
content of the support before and after treatment with papain
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was 98 (ta) and 47 (+2) mg/g silica, respectively. The original
amount of covalently linked antibodies following the
hydrazide-activated Support method was 1.6-fold larger than
that obtained by the aldehyde-activated silica support (Schiff
base) method, while the amount of antibodies remaining after
treatment with papain was 1.4-fold larger. The larger amount
of covalently linked antibodies in the hydrazide-activated
Support method compared to the aldehyde-activated silica
support (Schiffbase) method has been observed and may be
related to the more uniform orientation of antibodies in the

hydrazide-activated Support method. (See e.g., Clarke et al.,
(888.J. Chromatog. 13-22 (2000)). This difference compared
to the aldehyde-activated silica support (Schiffbase) method
may also reflect the more ordered orientation of antibodies in
the hydrazide-activated support method, which could have
made more F, regions accessible to papain for cleavage.
Without being limited by theory, however, these results may
vary with the type of antibody used. For example, anti-fluo
rescein mouse monoclonal antibodies retained by the
hydrazide-activated support method gave a 53% recovery of
activity after treatment with papain, which is similar to the
results noted in this section for rabbit IgG when using the
aldehyde-activated silica support (Schiffbase) method. Thus,
the method of covalently linking the antibody may affect the
preparation of the RAM.
The overall binding capacity of the support may further
depend on the activity of the covalently linked antibodies
along with the total antibody content and fraction of F,
regions present on the final material. For example, if there is
about a 50% retention of activity for F, regions in the alde
hyde-activated silica support (Schiffbase) method, the result
ing binding capacity for a RAM can be about 110 nmol/g
silica for a low mass target. If 85-100% retention of activity
occurs in the hydrazide-activated Support method, the result
ing binding capacity for a RAM can be about 104-122 nmol/g
silica for a low mass target even though fewer F, regions are
present in the final material. Therefore, slightly different val
ues may be obtained for other types of antibodies or when
using alternative methods for covalently linking the ligand
binding agent molecule.
Example 11

5
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RAM for Ultrafast Extraction

The RAM, specifically an IA-RAM made using anti-fluo
rescein antibody, was tested for use in a flow-based system for
the selective, ultrafast extraction of fluorescein versus a fluo
25

30

onto the anti-fluorescein RAM column and a control column
retention on the control column under the same conditions.
35

When the same experiment was performed with fluorescein
BSA, no significant degree of binding was seen on either the
RAM column or control column.

FIG. 8 illustrates how the extent of extraction varied using
40

different flow rates and residence times for contact between
fluorescein or fluorescein-BSA with the anti-fluorescein
RAM column. It was found that 90% of the fluorescein was
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extracted when using a contact time of 1.2 s and 80% fluo
rescein was extracted in 0.9s. Although this rate of extraction
was quite fast, it was slower than what has been noted for the
same type of antibodies on more traditional silica-based
immunoaffinity supports that have not been treated with
papain. This difference may be due to the decreased amount
of F, regions present in the anti-fluorescein RAM Support

Fluorescein and a fluorescein-BSA conjugate were used as
low mass and high mass target to evaluate the binding and
selectivity of a RAM prepared using covalently linked anti
fluorescein antibodies. Fluorescein was useful as a model for

Versus these other materials. Under the same conditions used
50

55

silica support with a pore size of 100 A by the hydrazide

for fluorescein, less than 1% of the fluorescein-BSA conju
gate was extracted by the anti-fluorescein RAM support.
Thus, a RAM support may be quite selective for a low mass
Versus high mass target when used under these conditions.
Example 13
Method for Preparing Restricted Access Media with
a Protected and Unbound Ligand Binding Agent or
Enzyme Molecule

activated Support method. A portion of this Support was set
aside for use as a reference while the remainder was treated

with papain for 90 minutes at 37°C. using an cleaving agent:
antibody ratio of 1:100 (w/w). The resulting RAM was
washed with PBS buffer to remove the cleaving agent and any
F, fragments cleaved from the antibodies. Known amounts
of the treated and original anti-fluorescein RAM were incu

60

bated for 30 minutes with an excess of fluorescein or fluores

65

cein-BSA conjugate to saturate any accessible binding
regions for these targets on the Support. The fluorescein or

rescein-BSA conjugate. This was accomplished by compar
ing the results obtained with a RAM column to results for a
control column containing only diol silica. The amount of
injected fluorescein or fluorescein-BSA in these studies was
1.5% or 20% of the total binding capacity for these two
analytes on the RAM support.
FIGS. 7(a) and (b) show chromatograms obtained when
fluorescein or fluorescein-BSA were injected at 0.1 mL/min

with no antibodies present. The fluorescein was quantita
tively extracted by the RAM column but gave no signs of

RAM in Static Binding

drugs or other low mass solutes because of its size (MW. 376
Da), its ease of detection, and the availability of monoclonal
anti-fluorescein antibodies. Fluorescein-BSA (MW, 69.5
kDa) was valuable as a model for a high mass target because
both BSA and its human counterpart HSA (MW, 66.5 kDa)
bind to a variety of drugs, hormones and other Small solutes.
Anti-fluorescein antibodies were covalently linked to a

22
fluorescein-BSA that was bound by anti-fluorescein antibod
ies was determined by determining the amount of the analytes
that remained in Solution after the incubation step.
The original binding capacity of the covalently linked anti
bodies was estimated using this approach to be 0.97 (+0.02)
ug/g silica for fluorescein or 0.69 (+0.01) mg/g silica for the
fluorescein-BSA conjugate. It was also found that the binding
capacity for fluorescein-BSA decreased by 92% (+3)% for
the anti-fluorescein support after treatment with papain.
However, the binding capacity for fluorescein decreased by
only 47 (+2)%. These results indicated that the treated Sup
port was more selective in binding to a low mass target Such
as fluorescein and gained some size selectivity, as would be
predicted for a RAM material.
Example 12

A Nucleosil silica support was converted into a hydrazide
activated form by treating a 500 mg quantity of the Support
with 3-glycidoxypropyltrimethoxysilane to introduce epoxy
groups onto the silica. The resulting epoxy silica Support was
treated with 0.1 M sodium acetate buffer (pH 5.5) by sonica
tion under vacuum for 10-15 minutes. 3-Glycidoxypropyltri
methoxysilane (5%-10% V/v) was added to the suspension
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and shaken for 5 hours at 90°C. The epoxy silica support was
washed several times with water and an aqueous Solution of
sulfuric acid (pH 3.0). The epoxy silica support was then
suspended in 100-150 mL of an aqueous sulfuric acid solu
tion (pH 3.0) and refluxed for one hour to convert the epoxy
silica Support into a diol form. The resulting diol silica Sup
port was washed with several portions of water, methanol and
ether. The diol content of the diol silica support was deter
mined using an iodometric capillary electrophoresis assay.
The diol silica Support was used to prepare an aldehyde
activated silica Support. To convert the diol groups to alde
hyde groups, 500 mg of the diol silica Support was suspended
in 10 mL of a 90% (v/v) mixture of acetic acid and water that
contained 500 mg periodic acid. This mixture was sonicated
under vacuum for 20 minutes and shaken on a wrist-action

shaker for 2 hours at room temperature. The resulting alde
hyde-activated silica was washed several times with water
and, 0.10M potassium phosphate buffer (pH 6.0). A 200 mg
quantity of the aldehyde-activated silica Support was sus
pended in 30 mL of 0.10 M potassium phosphate buffer (pH
5.0) that contained a 5-fold mole excess of oxalic dihydrazide
Versus the initial diol groups present in the added aldehyde
activated silica Support. The slurry was shaken for 2 hours at
room temperature on a wrist-action shaker. The Support was
then washed several times with 0.10 M potassium phosphate
buffer (pH 7.0). After activation, a 25-fold mol excess of
sodium borohydride (versus the initial diol groups) in 4 mL of
0.10 M potassium phosphate buffer (pH 8.0) was added in
several Small portions to the Support slurry to reduce any
remaining aldehyde groups. This mixture was shaken for 90
minutes at room temperature and washed several times with
0.10 M potassium phosphate buffer (pH 7.0). The final
hydrazide-activated support was stored in 0.10 M potassium
phosphate buffer (pH 7.0) at 4°C. until use.
Glycogen was oxidized for use as the oxidized polysaccha
ride by reacting a 5 mg/mL glycogen Solution with a 20
mg/mL Solution of periodate for 12 hours at room tempera
ture in a solution containing 20 mM sodium acetate, 0.15 mM
sodium chloride (pH 7.0). The oxidized glycogen was puri
fied using an Econo-Pac 10DG disposable column and 0.1 M
potassium phosphate buffer (pH 5.0).
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1000 A). Supports with 50 A pore size had the greatest
amount of retained HSA. Without being held to a particular
theory, the size of the glycogen capping agent may prevent it

from getting into pores Smaller than 300 A, making it easier
for glycogen to cap Such pores. As the pore size increased,
glycogen may have entered a greater number of pores, giving
a much smaller available volume for HSA retention.

Example 15
10

Restricted Access Media with Protected and

Unbound Alpha 1-Acid Glycoprotein
15

hydrazide-activated silica support having 100 A pore size for
25

A 50 mg/mL human serum albumin (“HSA) solution was
prepared in the 20 mM sodium acetate, 0.15 mM sodium
chloride (pH 7.0) solution. A 0.03 g quantity of hydrazide
activated silica support was mixed with 0.5 mL of the 50
mg/mL HSA solution and sonicated under vacuum for 15
minutes. A 100LL quantity of purified oxidized glycogen was
added to the support-HSA mixture and shaken for 24 hours at
room temperature. A 0.2 mL. Volume of a 2 mg/mL oxalic
dihydrazide solution was added during the last hour of the
reaction to cover any remaining aldehyde groups on the oxi
dized glycogen. The Support was then washed several times
with 0.1 M potassium phosphate solution (pH 7.0) and deion
ized water. Two control Supports were prepared in the same
manner but with no HSA or no oxidized glycogen added to
the hydrazide-activated silica. After preparation, the HSA and
control Supports were placed into separate 50 mmx2.1 mm
I.D. stainless steel columns using 0.067 M phosphate buffer
(pH 7.4).

As shown in FIG. 10, supports with pore sizes below 300 A
retained more HSA than larger pore size silica (500 A and

2 days at 4°C. The support was washed several times with 0.1
M potassium phosphate buffer (pH 7) and packed into a
10x2.1 mm I.D. stainless steel column using 0.067 M phos
phate buffer (pH 7.4) as the packing solution. Two control
supports were prepared in the same manner but with no AGP
or no oxidized glycogen added to the hydrazide-activated
silica during the retention step.
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Example 16
Activity of Protected and Unbound HSA in
Restricted Access Media
35

40

Example 14
Restricted Access Media with Protected and
Unbound Human Serum Albumin

A similar process used for obtaining restricted access
media with protected and unbound HSA was used to obtain
restricted access media with protected and unbound alpha
1-acid glycoprotein (AGP). A 25 mg sample of AGP was
dissolved in 0.5 mL. Volume of a 4.2 mg/mL oxidized glyco
gen in 0.1 M potassium phosphate buffer (pH 5). The AGP/
oxidized glycogen mixture was incubated with 0.15 g of
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Restricted access media with protected and unbound HSA
was examined for HSA activity using S-warfarin, which is
known to bind HSA. The binding capacities for the protected
and unbound HSA columns are summarized in Table 1. Using
the known content of HSA of these supports and the binding
capacities, the specific activity for the retained HSA was
determined. See, Table 1. The average specific activity was 91
(+29)%. This value was statistically equivalent to 100% and
significantly higher than the specific activity reported for
covalently immobilized HSA (see, Loun et al. 66Anal. Chem.
3814-3822 (1994)). Association equilibrium constants also
were determined for S-warfarin with retained HSA. Results

are summarized in Table 1. Values ranged between 1.4 and
50

2.0x10 M' at pH 7.4 at 37° C. These values were in good
lized HSA (e.g., 2.0x10 M') (see, Loun et al. 66 Anal.

agreement with those reported for soluble HSA and immobi
Chem. 3814-3822 (1994)).
TABLE 1
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Binding capacity and specific activity for S-warfarin on
HSA Retained RAM columns.
Association
60

Binding Capacity
Equilibrium Constant
Pore Size
(x10 mol)
Specific Activity
(x10M)

65

1000 A
500 A
300 A
100 A
50 A

1.3 (+/-0.2)
1.8 (+/-0.2)
1.6 (+/-0.2)
1.8 (+/-0.2)
2.1 (+/-0.2)

1.1 (+/-0.2)
1.29 (+/-0.17)
0.73 (+/-0.11)
0.85 (+/-0.11)
0.56 (+/-0.11)

2.0 (+/-0.3)
1.4 (+/-0.2)
1.5 (+/-0.2)
NA
1.9 (+/-0.2)
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The discussion of the references herein is intended merely
to Summarize the assertions made by their authors and no
admission is made that any reference constitutes prior art.
Applicant reserves the right to challenge the accuracy and
pertinence of the cited references.

5

In view of the above, it will be seen that the several advan

tages of the invention are achieved and other advantageous
results attained. As various changes could be made in the
above methods and compositions without departing from the
Scope of the invention, it is intended that all matter contained
in the above description and shown in the accompanying
drawings shall be interpreted as illustrative and not limiting.
Thus, the breadth and scope of the present invention should
not be limited by any of the above-described exemplary
embodiments, but should be defined only in accordance with
the following claims appended hereto and their equivalents.
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What is claimed is:

1. A restricted access media comprising a Support wherein
a plurality of protected regions of said Support contain one or
more unbound ligand binding agent(s) or enzyme molecules,
and wherein said unbound ligand binding agent(s) or enzyme
molecule(s) are retained in said protected regions by a cap
ping agent that is bound to said Support, and wherein said
ligand binding agent(s) or enzyme molecule(s) are not bound
to said Support.

Support.
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2. The restricted access media of claim 1, wherein said

Support comprises an inorganic material, a biological mate
rial, an organic material, an organic polymer, a composite
Support, or a modified Support.

3. The restricted access media of claim 1, wherein said

4. The restricted access media of claim 1, wherein said
5. The restricted access media of claim 4, wherein said

carbohydrate containing agent comprises glycogen, dextran,
agarose, or cellulose.

8. The method of claim 6, wherein said activated support is
activated by a hydrazide group, an amine group, an aldehyde
group, or a combination thereof.
9. The method of claim 6, wherein said unbound ligand
binding agent or enzyme molecule comprises a protein, a
glycoprotein, a DNA, a RNA, a nucleoprotein, a carbohydrate
containing agent, a lipoprotein, or a combination thereof.
10. The method of claim 6, wherein said support comprises

a porous support with a pore size of about 50 A to about 1000
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unbound ligand binding agent comprises a protein, a glyco
protein, a DNA, a RNA, a nucleoprotein, a carbohydrate
containing agent, a lipoprotein, or a combination thereof.
capping agent comprises a glycoprotein, a glycolipid, a car
bohydrate containing agent, or a combination thereof.
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6. A method for preparing a restricted access media com
prising:
a) incubating an activated Support with a solution compris
ing: i) aligand binding agent oran enzyme molecule and
ii) an activated capping agent; and
b) removing unbound capping agent from said incubated
Support, thereby preparing the restricted access media
comprising a Support wherein a plurality of protected
regions of said Support contain one or more unbound
ligand binding agent(s) or enzyme molecule(s) and
wherein said unbound ligand binding agent(s) or
enzyme molecule(s) are retained in said protected
regions by said capping agent that is bound to said Sup
port, and wherein said ligand binding agent(s) or
enzyme molecule(s) are not bound to said Support.
7. The method of claim 6, wherein said ligand binding
agent or said enzyme molecule and said activated capping
agent are incubated together or separately with said activated
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11. A kit comprising a restricted access media that com
prises comprising: i) a Support wherein a plurality of pro
tected regions of said support contain one or more unbound
ligand binding agent or enzyme molecules, and wherein said
ligand binding agent(s) or enzyme molecules are retained in
said protected regions by a capping agent that is bound to said
Support, and wherein said ligand binding agent(s) or enzyme
molecule(s) are not bound to said Support, and ii) at least one
container.

